The impact of Artificial Intelligence in the pharmaceutical industry

Artificial Intelligence (AI) has emerged as a transformative force in various industries, and the field of drug discovery is no exception. AI-powered technologies have revolutionized the way pharmaceutical research is conducted, accelerating the discovery and development of new drugs. By leveraging machine learning algorithms, data analytics, and predictive modelling, AI offers unprecedented opportunities for efficiency, precision, and cost-effectiveness in the drug discovery process. In this article, we will explore the current state of the Artificial Intelligence in Drug Discovery Market, its key players, applications, challenges, and the potential impact on the future of healthcare.

Traditional drug discovery is a complex and lengthy process that involves the identification of potential therapeutic compounds, followed by preclinical and clinical testing before reaching the market. This process typically takes many years and involves significant financial investments. However, despite these efforts, the success rate of bringing a new drug to market remains low, with high rates of failure during clinical trials. This inefficiency has prompted the pharmaceutical industry to seek innovative solutions, and AI has emerged as a game-changer.

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Poolbeg Pharma

More articles like this

Poolbeg Pharma’s Cathal Friel assumes role of Executive Chairman

Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced a change of Board role and the Remuneration Committee’s approval of

What will cancer therapy look like in 2034?

Drugs like PARP inhibitors and chimeric antigen receptor (CAR) therapies, and advancements in artificial intelligence in drug discovery, have spurred hope for improved cancer care in the past year. Rigorous research has paved the way for a

Reducing cancer immunotherapy-induced CRS

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.